-+ 0.00%
-+ 0.00%
-+ 0.00%

Acurx Pharmaceuticals Q3 net loss widens 30% to $2.58 million

PUBT·11/12/2026 12:18:34
Listen to the news
Acurx Pharmaceuticals Q3 net loss widens 30% to $2.58 million
  • Acurx Pharmaceuticals’ third-quarter 2026 net loss widened 30% year over year to $2.58 million.
  • Research and development expenses more than doubled to $1.12 million, due primarily to higher consulting costs for the recurrent CDI trial program.
  • Cash totaled $9.65 million at September 30, 2026, up 28% from December 31, 2025.
  • The fully funded, 20-patient PATHFINDER trial of ibezapolstat in multiply recurrent CDI began enrollment September 29, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611120701PR_NEWS_USPR_____NY88234) on November 12, 2026, and is solely responsible for the information contained therein.